Results 161 to 170 of about 2,233,785 (258)

Fucosylation limits ADCC in clinically used anti‐RhD monoclonal antibodies

open access: yesTransfusion, Volume 66, Issue 11, Page 2360-2372, November 2026.
Abstract Background Haemolytic disease of the fetus and newborn (HDFN) is caused by maternal alloantibodies, often targeting the D antigen on fetal red blood cells. Maternal immunization is preventable with timely administration of anti‐D polyclonal antibodies (pAbs).
Gabriela Koike   +33 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

open access: yesTransfusion, Volume 66, Issue 11, Page 2421-2431, November 2026.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman   +4 more
wiley   +1 more source

Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding

open access: yesTransfusion, Volume 66, Issue 11, Page 2323-2334, November 2026.
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy